Dr. Golumbeski has served as a partner at DROIA Ventures, a venture capital firm focused on therapeutics for oncology and genetic disease, since October 2020 and previously served as the President and Head of Corporate Development for GRAIL, Inc. from August 2018 to September 2019. From 2009 to April 2018, Dr. Golumbeski served as Executive Vice President of Business Development for Celgene Corporation (“Celgene”). Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing, and Strategy at Novartis. Dr. Golumbeski has served on the board of Shattuck Labs, Inc. since January 2018, and he serves on the boards of directors of various private companies. He also previously served on the boards of directors of Sage Therapeutics, Inc., MorphoSys AG and Enanta Pharmaceuticals, Inc. Dr. Golumbeski received a B.A. in Biology from the University of Virginia and a Ph.D. in genetics from the University of Wisconsin—Madison. The Board believes Dr. Golumbeski is qualified to serve as a director based on his significant experience in research and development, business development and leadership at various pharmaceutical companies.